President Trump’s recent Executive Order to reclassify marijuana from a Schedule I to a Schedule III drug under the Drug Enforcement Administration has sparked debate about the future of workplace drug testing. Schedule I drugs are defined as having no accepted medical use and a high potential for abuse, while Schedule III drugs are considered to have a lower potential for dependence.Despite possible reclassification, most employers conduct drug testing primarily to promote workplace safety — the top reason cited in Current Consulting Group’s 2025 employer survey. Employers also report improved employee quality, reduced legal risks, and enhanced productivity as key benefits. Research showing high rates of on-the-job marijuana use, along with increased workers’ compensation claims in states with recreational marijuana laws, reinforces employer concerns about impairment and safety.Listen to the latest episode of Currently Speaking to learn more about how rescheduling marijuana will impact drug testing in 2026.